TD Cowen initiated coverage of Intuitive Surgical (ISRG) with a Buy rating and a $660 price target, citing the launch of the da Vinci 5 system. Analysts expect this new system to drive both fleet expansion and the replacement of older systems, with refurbished prior-generation platforms being redeployed into more price-sensitive markets. This strategy is anticipated to broaden access and increase procedure volumes.

The firm's thesis centers on a 'ripple effect' from the da Vinci 5 rollout, which is believed to be in its early stages globally. TD Cowen expects efficiency gains from the new system to increase throughput at existing sites, while the wider placement of refurbished Xi systems could allow hospitals to perform more complex procedures. This dynamic is not yet fully reflected in current market expectations.

A proprietary survey of heads of large robotic surgery programs supports this view. About half of respondents indicated that new robotic purchases would expand their fleets and increase institutional capacity. Roughly 30% expected a mix of expansion and redeployment of older systems. Despite some anticipated purchases of non-Intuitive systems, nearly 80% of expected purchases over the next two years are projected to be Intuitive’s da Vinci systems. This suggests a continued stronghold in the market.

Intuitive Surgical trades at a premium to large-cap medtech peers, reflecting its scarcity value in a secular growth story tied to the shift toward minimally invasive surgery and its broad ecosystem of surgeons and technology. The $660 price target is based on a 65x multiple of its above-consensus 2026 earnings estimate, indicating strong confidence in the company’s growth trajectory.